Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 9OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Solid Tumors 1Neoplasms 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × vadimezan × Clear all
NCT01031212 2013-05-13

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

University of California, San Francisco

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT00863733 2009-03-18

DMXAA

Cancer Research UK

Phase 1 Completed
63 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡